Conference Coverage

Absolute increase in Kawasaki CV risk remains small in long-term follow-up


 

FROM THE ANNUAL MEETING OF THE CANADIAN RHEUMATOLOGY ASSOCIATION

Severity of acute disease might matter

During the acute phase of Kawasaki disease, the arterial damage varies. As suggested in the University of Lausanne follow-up, patients with significant coronary aneurysms do appear to be at greater risk of long-term complications. Dr. Gaensbauer cited a statement from the American Heart Association that noted a higher risk of CV sequelae from Kawasaki disease with a greater or more severe coronary aneurysm or in the face of other evidence of damage to the arterial tree.

“The clinical course within the first 2 years of Kawasaki disease appears to be important for risk of CV complications after this time,” Dr. Gaensbauer said.

The absolute risk of CV events in patients with a more complicated acute course of Kawasaki disease remains incompletely understood, but Dr. Gaensbauer said that there are several sets of data, including these new data from the Hospital for Sick Children, that suggest that the overall prognosis is good. However, he cautioned that this reassurance does not necessarily apply to children with a difficult acute course.

According to the 2017 AHA statement on Kawasaki disease, risk stratification based on echocardiography and other measures after the acute phase of Kawasaki disease are reasonable to determine if long-term follow-up is needed. In those without abnormalities, it is reasonable to forgo further cardiology assessment.

Dr. Lee and Dr. Gaensbauer reported having no potential conflicts of interest.

Pages

Recommended Reading

Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
MDedge Rheumatology
Synthetic chemical in consumer products linked to early death, study says
MDedge Rheumatology
Adalimumab biosimilar Cyltezo gets interchangeability designation
MDedge Rheumatology
FDA panel votes to approve Pfizer’s vaccine for children
MDedge Rheumatology
FDA authorizes Pfizer’s COVID-19 vaccine for kids
MDedge Rheumatology
Drug combo at outset of polyarticular JIA benefits patients most
MDedge Rheumatology
Step right up, folks, for a public dissection
MDedge Rheumatology
Penicillin slows latent rheumatic heart disease progression
MDedge Rheumatology
COVID-19 linked to increased diabetes risk in youth
MDedge Rheumatology
COVID-vaccine myocarditis: Rare, mild, and usually in young men
MDedge Rheumatology